Computerized Ultrasound Risk Evaluation (CURE) system, developed by KCI and SciTech, will fulfill the mission to provide a significant clinical improvement at a reduced cost. The CURE research & development team’s enhancement of ultrasound technology has resulted in imaging capabilities superior to current devices. 

Utilizing the existing ring array configuration, experiments have been preformed to show that time reversal (TR) focusing could be used in non-invasive drug delivery procedure. TR focusing uses an iterative approach to determine the waveform required for transmittal from each element of the array to achieve the optimum focusing on a selected target. The major potential benefit for breast imaging and treatment would be that TR focusing is not susceptible to distorting mediums, such as the highly scattering combination of breast fat and parenchyma. Using the TR approach, ultrasound has the potential to be tightly focused in tissue for the treatment of cancerous tumors, using either direct ablation or targeted drug delivery via local rupture of liposomes containing a therapeutic agent. Specialized drug formulations and dosage forms are being devised to match the technical specifications of the CURE system so that tissue exposure occurs only at the exact area(s) of breast disease identified by the CURE system.

18 million mammograms are conducted annually in the US, and yet 10-15% evaded cancer detection. Even though women with suspicious masses have a follow-up ultrasound (US), breast cancer remains the second leading cause of death for woman. An obvious need exists for better, more reliable and accurate technology.